Atara Biotherapeutics, Inc (ATRA)

Etorro trading 970x250
Atara Biotherapeutics, Inc (ATRA) Logo

About Atara Biotherapeutics, Inc

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080

Atara Biotherapeutics, Inc News and around…

Latest news about Atara Biotherapeutics, Inc (ATRA) common stock and company :

First Week of June 2022 Options Trading For Atara Biotherapeutics (ATRA)
15 Oct, 2021 FinancialContent

Investors in Atara Biotherapeutics Inc (ATRA) saw new options begin trading this week, for the June 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

50 Biggest Movers From Yesterday
14 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated ...

Analysts Anticipate 15% Upside For The Holdings of ESGV
13 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard ESG US.

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
13 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar ...

Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
13 Oct, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase 1 open-label extension (OLE) clinical data in patients with progressive multiple sclerosis (MS) treated with ATA188 for up to 39 months.

Atara Biotherapeutics Shows Rising Price Performance With Jump To 83 RS Rating
13 Oct, 2021 FinancialContent

Atara Biotherapeutics sees its Relative Strength Rating move into the 80-plus level.

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
10 Oct, 2021 FinancialContent

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.

Atara Biotherapeutics Shows Improved Relative Strength; Still Shy Of Benchmark
06 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Atara Biotherapeutics shows improving technical performance. Will it continue?

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
04 Oct, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America.

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
01 Oct, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 104,386 restricted stock units of Atara’s common stock to 16 newly hired employees and stock options to purchase an aggregate of 107,813 shares of Atara’s common stock to five such newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of October 1, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

We're Not Very Worried About Atara Biotherapeutics' (NASDAQ:ATRA) Cash Burn Rate
01 Oct, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Atara Biotherapeutics Sees IBD RS Rating Rise To 72
30 Sep, 2021 FinancialContent

Atara Biotherapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
29 Sep, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) clinical data from the study of ATA188 in progressive multiple sclerosis (MS). The findings will be presented as an ePoster at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place virtually October 13-15, 2021.

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
27 Sep, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Company’s lead product candidate, tabelecleucel (tab-cel®), for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
02 Sep, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled, “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” at the Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9, 2021 at 7:40 a.m. PDT/10:40 a.m. EDT.

Noteworthy ETF Outflows: LABU, ARNA, ARWR, ATRA
27 Aug, 2021 FinancialContent

Symbols mentioned in this story: LABU, ARNA, ARWR, ATRA Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Atara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcript
10 Aug, 2021 FinancialContent

ATRA earnings call for the period ending June 30, 2021.

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
09 Aug, 2021 Yahoo! Finance

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -3.41% and -38.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
09 Aug, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2021, recent business highlights and key catalysts over the next several months.

Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
09 Aug, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial launch of its lead product, tab-cel®.

Understanding Atara Biotherapeutics's Unusual Options Activity
09 Aug, 2021 FinancialContent

On Monday, shares of Atara Biotherapeutics (NASDAQ:ATRA) saw unusual options activity. After the option alert, the stock price moved ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

The Math Shows VTWV Can Go To $164
03 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $163.71 per unit.

Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
02 Aug, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Could Be 37% Below Their Intrinsic Value Estimate
02 Aug, 2021 Yahoo! Finance

Today we will run through one way of estimating the intrinsic value of Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) by...

Is Atara Biotherapeutics Inc (ATRA) A Good Stock To Buy?
21 Jul, 2021 Yahoo! Finance

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

First Week of March 2022 Options Trading For Atara Biotherapeutics
16 Jul, 2021 FinancialContent

Investors in Atara Biotherapeutics Inc (ATRA) saw new options begin trading this week, for the March 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Bag This Bargain Even Cheaper Than Chief Commercial Officer Yarema Did
07 Jul, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on June 14, Atara Biotherapeutics Inc's Chief Commercial Officer, Kristin Yarema, invested $500,369.64 into 34,354 shares of ATRA, for a cost per share of $14.57..

Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
01 Jul, 2021 FinancialContent

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company has joined the Rare Disease Company Coalition. The coalition represents an alliance of innovative life sciences companies committed to discovering, developing and delivering rare disease treatments for the patients they serve.

Atara Biotherapeutics, Inc (ATRA) is a NASDAQ Common Stock listed in , ,

970x250